Pfizer Inc. (PFE) Stock: The Numbers Look Good?

Analysts at Cantor Fitzgerald, assumed coverage of Pfizer Inc. (NYSE:PFE) with Overweight recommendation, according to their opinion released on June 08. Barclays analysts have downgraded their rating of PFE stock from Overweight to Equal Weight in a separate flash note to investors on April 05. Analysts at SunTrust are sticking to their Hold recommendation. However, on January 29, they lifted target price for these shares to $40 from $33. Analysts at SunTrust, made their first call for the stock with a Hold rating, according to a research note that dated back to January 29.

By watching the trading activity of corporate insiders, it will become easier to get a sense of Pfizer Inc. (NYSE:PFE)’s prospects. The earliest insider trade took place on 08/13/2018. Olson Laurie J parted with a total of 10.21 thousand shares of company at average share price of $41. The total for the sales was set at $418.77 thousand. After this transaction, the Executive Vice President account balance stood at 78.2 thousand shares. The stock grew 7.15 percent since that insider sale. On 08/03/2018, Mackenzie Alexander R, Executive Vice President, sold 25.64 thousand shares at a price per share of $39.51. This removed 1.01 million shares from the insider’s fortune and the stock saw a 11.19 percent rally in value since the news became public. This transaction left 111.53 thousand shares in the Executive Vice President account. On 08/01/2018, Executive Vice President Damelio Frank A performed a sale transaction worth $6.02 million. This sale at $40 each has eliminated 150.48 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded 9.82 percent increase since the transaction was reported. The insider now is left with 342.45 thousand shares remaining in the account. Lund-Jurgensen Kirsten, who performs the Executive Vice President job, sold 20.94 thousand shares for $838.52 thousand. The disposal occurred on 08/01/2018 was priced at $40.04 per share. The share price soared 9.72 percent since the reporting date. Lund-Jurgensen Kirsten now left with a stake of 4.64 thousand PFE stock worth $203.97 thousand after the insider selling.

Pfizer Inc. (PFE) is expected to jump by -3.32 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $48-month high price target. This represents a whopping 9.26 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $45, which represents a return potential of 2.44 percent when compared to the closing price of the stock of $43.93 on Tuesday, October 16. The lowest price target for the stock is $34 — slightly more than -22.6 percent from PFE’s current share price.

The shares are currently floating around the first support level of $43.32. Below this, the next support is placed in the zone of $42.71. Till the time, the PFE stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 51.68 on daily chart, which may remain a cause for concern. If the price breaks below $42.71 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $44.26 mark may result into a pull-back move towards $44.59 level.

PFE shares accumulated 0.81 points or 1.88 percent on Tuesday to $43.93 with a light trade volume of 20.529 million shares. After opening the session at $43.35, the shares went as high as $43.98 and as low as $43.04, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $258 billion and now has 5.87 billion shares outstanding. Pfizer Inc. (PFE) stock has gained 2.14 percent of market value in 21 trading days.

PFE stock has a trailing 3-year beta of 0.88, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was $2.18 a share in the trailing twelve months. The stock’s value has surged 21.29 percent year to date (YTD) against a rise of 22.1 percent in 12 month’s time. The company’s shares still trade -4.1 percent away from its 1-year high of $45.81 and 32.32 percent up from 52-week low of $33.20. The average consensus rating on the company is 2.7, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.

Shares of Pfizer Inc. (PFE) are trading at a P/E ratio of 20.75 times earnings reported for the past 12 months. The industry PFE operates in has an average P/E of 29.75. Its P/E ratio went as low as 18.43X and as high as 29.07 over the 5-year span. Further, it is sporting a 4.84 on the Price-to-Sales ratio. Compare this with the industry average P/S of 4.59. 78.9 percent is the gross profit margin for Pfizer Inc. and operating margin sits at 25.4 percent. Along with this, the net profit margin is 42.3 percent.

Analysts are forecasting revenue to climb 2.9 percent to $13.6B in the next fiscal quarter, while earnings are seen soaring by nearly 11.94 percent to $0.75 per share. History has shown that shares in Pfizer Inc. have gone down on 20 different earnings reaction days and are predicted to add 0.01 percent when the company reports upcoming earnings. In last reported earnings results, it earned $0.81 per share, better than the $0.74, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $13.5B, better than the $13.3B analysts expected. Earnings are estimated to increase by 68.2 percent this year, 3.48 percent next year and continue to increase by 7.52 percent annually for the next 5 years.